Posted by Michael Wonder on 05 Aug 2015

Schedule of Pharmaceutical Benefits - 1 August 2015 update

PBAC

The August 2015 issue of the Schedule of Pharmaceutical Benefits is out and now in effect. The Schedule inclides the following new and revised listings:

  • Adalimumab (Humira) - new indication
  • Amino acid formula with vitamins and minerals without phenylalanine (PKU Air 15, PKU Air 20) - new formulation
  • Apixaban (Eliquis) - new indication
  • Ezetimibe with atorvastatin calcium (Atozet) - new formulation
  • Glatiramer acetate (Copaxone) - new strength
  • Glucose indicator (Betachek C50) - new formulation
  • Obinutuzumab (Gazyva) - new listing
  • Pomalidomide (Pomalyst) - new listing
  • Testosterone (Testogel) - new formulation
  • Testosterone (AndroForte 5) - new formulation
  • Trametinib dimethyl sulphoxide (Mekinist) - new listing
  • Triglycerides – medium chain (Nutrini Peptisorb) - new formulation
  • Vedolizumab (Entyvio) - new listing (2 indications)

​For more details, go to: http://www.pbs.gov.au/browse/changes

 

Michael Wonder

Posted by:

Michael Wonder

Posted in: